Diabetes is a growing problem around the world. The incidence of diabetes is set to rise from 346 million today to 472 million in 2030, and the World Health Organization predicts that diabetes will become the seventh leading cause of death by 2030. Although it is a global problem, more than 80% of diabetes-related deaths occur in low- and middle-income countries.

Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Hyperglycemia, or high blood sugar, is a common effect of uncontrolled diabetes and over time leads to serious damage to many of the body’s systems.
There are three commonly recognized forms of diabetes:

  • Type 1 diabetes is characterized by absent insulin production and requires daily administration of insulin. The cause is not known, and it is not preventable.
  • Type 2 diabetes comprises 90%of people with diabetes around the world and is largely the result of excess body weight and physical inactivity. Symptoms may be similar to those of Type 1 diabetes but are often less marked. As a result, the disease may be diagnosed several years after onset, once complications have already arisen.
  • Gestational diabetes occurs during pregnancy. It is most often diagnosed through prenatal screening, rather than reported symptoms.

In addition, there is an intermediate condition known as impaired glucose tolerance (IGT) and impaired fasting glycaemia. People with this condition are at high risk of progressing to Type 2 diabetes. People with IGT often have no symptoms, yet early diagnosis and intervention can help prevent or delay progression to overt diabetes.

Since 1923, Lilly has pioneered therapies to help healthcare providers improve the lives of people with diabetes, and Lilly continues to research innovative medicines to address unmet medical needs. The Lilly NCD Partnership focuses on improving outcomes for people at risk of diabetes.